BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: 89bio, Inc. (Nasdaq - ETNB), Barinthus Biotherapeutics plc (Nasdaq - BRNS), Verint Systems Inc. (Nasdaq - VRNT), Dayforce, Inc. (NYSE- DAY)
1. Roche to acquire 89bio, Inc. for $14.50 per share.
2. Acquisition includes potential milestone payments of up to $6.00 per share.
3. Investigation on 89bio's fiduciary duties regarding fairness in the process.
4. Deal may be scrutinized for not offering fair value to shareholders.
5. Shareholder interests in M&A may influence Roche's stock performance.
The acquisition of 89bio represents a strategic move for Roche, potentially enhancing its portfolio. Historically, successful acquisitions have bolstered share prices when perceived as adding value.
How important is it?
The acquisition of 89bio can lead to increased market confidence in Roche's innovative pipeline, positively influencing RHHBY's stock. Strong market perceptions around M&A activities can markedly affect similar biopharmaceutical stocks.
Why Long Term?
Acquisitions typically take time to integrate and reflect in stock performance, affecting long-term prospects positively. Previous Roche acquisitions have shown gradual positive trends in stock value post-integration.
BALA CYNWYD, Pa., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
89bio, Inc. (Nasdaq - ETNB)
Under the terms of the Merger Agreement, 89bio will be acquired by Roche ((SIX: RO, ROG, OTCQX:RHHBY) for $14.50 per share in cash, plus a non-tradeable contingent value right (CVR) to receive certain milestone payments of up to an aggregate of $6.00 per share in cash. The investigation concerns whether the 89bio Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company's shareholders.
Under the terms of the Merger Agreement, Barinthus will merge with Clywedog Therapeutics, Inc. ("Clywedog"). Shareholders of Barinthus will receive one share of common stock in the new combined company for each American Depositary Share ("ADS") or ordinary share owned, and each stockholder of Clywedog will receive 4.358932 shares of common stock in the new combined company for each common or preferred share owned. Upon the close, shareholders of Barinthus are expected to own approximately 34%, and the stockholders of Clywedog are expected to own approximately 66% of the combined company on a fully diluted basis. The investigation concerns whether the Barinthus Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company's shareholders.
Under the terms of the Merger Agreement, Dayforce will be acquired by Thoma Bravo for $70.00 per share in cash in a deal with an enterprise value of $12.3 billion. The investigation concerns whether the Dayforce Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company's shareholders. For example, the deal consideration is below the 52-week high of $82.69 for the Company's shares.
Under the terms of the Merger Agreement, Verint will be acquired by Thoma Bravo for $20.50 in cash for each share of Verint they own. The investigation concerns whether the Verint Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the consideration provides fair value to the Company's shareholders. For example, the deal consideration is below the 52-week high of $34.80 for the Company's shares.
Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.
